Drug shortages
Leading healthcare groups convened a summit, “Safe, Effective, and Accessible High-Quality Medicines as a Matter of National Security,” on July 27-31 to examine the resilience of the U.S. pharmaceutical supply chain in light of the current state of global pharmaceutical manufacturing.
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D-Ore., and Gus Bilirakis, D-Fla., introduced the Preventing Drug Shortages Act (H.R. 6080).
AHA, health organizations letter to Senate Chairman, Lamar Alexander and Ranking Member Patty Murray, expressing support of S.2723 - The Mitigating Emergency Drug Shortages (MEDS) Act.
AHA, health organizations letter to Representatives Peters, Engel, Eshoo, Schrader, Guthrie, Hudson, McCaul, and Bilirakis, supporting the Preventing Drug Shortages Act.
AHA, others urge Senate HELP Committee to advance MEDS Act (S.2723).
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to import certain FDA-approved prescription drug and biological products from Canada.
Drug shortages threaten the quality of patient care, narrow treatment options and often result in the use of potentially less effective alternative medications, hospital and health system leaders said at a briefing today on Capitol Hill.
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe Medication Practices today voiced strong support for the Mitigating Emergency Drug Shortages Act.
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe Medication Practices voiced strong support for the Mitigating Emergency Drug Shortages Act (S.2723), which includes provisions recommended by a…
The Food and Drug Administration approved a record high 1,171 generic drugs in fiscal year 2019, the agency said today.